lost an estimated 1-1.5 million dollars of ad revenue, and lost its husband and wife editing team a year later. 4 The recent split of the American Journal of Hypertension and the American Society of Hypertension-the Journal's Editor maintaining the society had become a marketing arm of the pharmaceutical industry, is another example.
5
In 2001, we had raised concerns about a decision by the SGIM Council to accept $200,000 from the very same ''ABC drugs'' that commissioned the ghost-written piece. 6 Following vocal opposition by members, the council reversed their decision. Since then, SGIM has wisely adopted external funding rules that have allowed it to remain free of such influence. 7 Professional societies and pharmaceutical companies have different primary interests and objectives. Medical society dependence on industry ''support'' may lead to confusion of these interests. An example was the announcement by another medical organization of the creation of a health policy institute through a $750,000 grant from the very same ''ABC drugs.'' 8 The press release notes that a pharmaceutical executive will have substantial input in creating the institute's ''long-term strategic and operational plans.'' 7 The SGIM-ABC ''collaboration'' would have been another example of such a potential conflict. We in the profession must not allow our goals to be subverted, and medical societies-and their journals-must lead the way. We urge other organizations to adopt external funding policies similar to those of SGIM.-Robert L. Goodman, MD, Olveen Carrasquillo, MD, MPH, Columbia University College of Physicians and Surgeons, Division of General Medicine, New York, NY.
